Medgenics starts trading on AIM
Medgenics, a US incorporated holding company of a biopharmaceutical group, says that its issued shares of common stock of par value of $0.0001 each have been admitted to trading on the UK's Alternative Investment Market, and dealings started on December 4. The admission to the AIM follows the company's successful fund raising which raised a total of nearly L3.3 million ($6.8 million).
The group's R&D and administrative operations are conducted by Medgenics Medical (Israel) Limited, the company's wholly-owned subsidiary, from premises in Karmiel, Israel.
The Group is at the clinical trial stage of testing the safety and efficacy of its proprietary "biological pump" and associated technologies for producing and delivering therapeutic proteins in patients, together the Biopump Platform Technology.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze